EZH2 and epithelioid sarcoma: Recently, EPZ‐6438 has been approved by FDA as the first EZH2 inhibitor for the treatment of epithelioid sarcoma,35 and EPZ‐6438 treatment inhibited the progression of several cancers.36, 37, 38